- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01338714
The Effect of Compound Herbal Formula (RHD-1) on HBV Carrier With Abnormal Liver Function
May 6, 2014 updated by: Chung-Hua Hsu, Taipei City Hospital
The Effect of Compound Herbal Formula (RHD-1) on HBV Carrier With Abnormal Liver Function: a Randomized Controlled Trial
The aim of the study is to examine whether the compound herbal formula (RHD-1) is effective on HBV Carrier With Abnormal Liver Function.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
% change HBV DNA title and liver function.
Study Type
Interventional
Enrollment (Actual)
58
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Taipei, Taiwan, 886
- Taipei City Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 40 < GPT <200 HBV carrier Age: 18-65 yrs old
Exclusion:
Creatinine >2.0 mg/dL Total bilirubin > 2.0mg/dL Not suitable patients diagnosis by physician in charge.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A foumula
Compound Herbal Formula (RHD-1)
|
100 ml/per day
Other Names:
|
Placebo Comparator: B formula
dilute Compound Herbal Formula
|
100 ml/per day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
the % change of HBV DNA title
Time Frame: 6 weeks
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
the % change of GPT
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Hsu CH, Hwang KC, Chiang YH, Chou P. The mushroom Agaricus blazei Murill extract normalizes liver function in patients with chronic hepatitis B. J Altern Complement Med. 2008 Apr;14(3):299-301. doi: 10.1089/acm.2006.6344.
- Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology. 2002 Dec;36(6):1408-15. doi: 10.1053/jhep.2002.36949.
- Lee CJ, Cheng CH, Li YH, Liu CY, Hsu CH. A Chinese medicine, Kuan-Sin-Yin decoction, improves liver function in hepatitis B virus carriers: a randomized, controlled study. J Altern Complement Med. 2013 Dec;19(12):964-9. doi: 10.1089/acm.2013.0136. Epub 2013 Jul 17.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2011
Primary Completion (Actual)
June 1, 2012
Study Completion (Actual)
September 1, 2012
Study Registration Dates
First Submitted
April 18, 2011
First Submitted That Met QC Criteria
April 18, 2011
First Posted (Estimate)
April 19, 2011
Study Record Updates
Last Update Posted (Estimate)
May 7, 2014
Last Update Submitted That Met QC Criteria
May 6, 2014
Last Verified
May 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 100001-62-010
- 100-00-62-01 (Other Grant/Funding Number: 100-00-62-01A)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Dysfunction
-
Loma Linda UniversityWithdrawnLiver Graft Dysfunction
-
National Cancer Institute (NCI)Completed
-
University of AthensCompleted
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruiting
-
Bausch Health Americas, Inc.CompletedLiver DysfunctionUnited States
-
Chong Kun Dang PharmaceuticalCompletedLiver DysfunctionKorea, Republic of
-
University of AlbertaRecruitingLiver DysfunctionUnited States, Australia, Canada, Poland, United Kingdom
-
Zhejiang Medicine Co., Ltd.Huashan HospitalCompleted
-
PfizerCompletedMild Hepatic Dysfunction | Moderate Hepatic DysfunctionSouth Africa
-
Hospices Civils de LyonCompletedLiver Transplant; Complications | Myocardial DysfunctionFrance
Clinical Trials on Compound Herbal Formula (RHD-1)
-
Abbott NutritionCompletedGastrointestinal ToleranceUnited States, Canada
-
Chi Mei Medical HospitalGeneFerm Biotechnology Co., Ltd.Completed
-
Abbott NutritionCompleted
-
Xiaofei YuShanghai Municipal Science and Technology CommissionCompleted
-
HiPP GmbH & Co. Vertrieb KGTerminatedInfantile ColicGermany, Italy
-
Vanquish Oncology, Inc.University of Illinois at ChicagoCompletedSolid Tumor | Neuroendocrine Tumors | Pancreatic Neuroendocrine TumorUnited States
-
HiPP GmbH & Co. Vertrieb KGCharite University, Berlin, GermanyCompletedDisturbance of GrowthGermany, Austria, Serbia
-
NestléCompleted
-
Dalin Tzu Chi General HospitalRecruitingTinnitus | Sleep DisturbancesTaiwan
-
ShuGuang HospitalUnknownHemorrhagic StrokeChina